DQP 1105CAS# 380560-89-4 |
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Saracatinib (AZD0530)
Catalog No.:BCC1166
CAS No.:379231-04-6
- Nilotinib(AMN-107)
Catalog No.:BCC3643
CAS No.:641571-10-0
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 380560-89-4 | SDF | Download SDF |
PubChem ID | 6044308 | Appearance | Powder |
Formula | C29H24BrN3O4 | M.Wt | 558.42 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 4-[(3Z)-5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenylquinolin-3-ylidene)pyrazolidin-1-yl]-4-oxobutanoic acid | ||
SMILES | CC1=CC2=C(C(=C3CC(N(N3)C(=O)CCC(=O)O)C4=CC=C(C=C4)Br)C(=O)N=C2C=C1)C5=CC=CC=C5 | ||
Standard InChIKey | CADIBCWPGCNUBD-NFFVHWSESA-N | ||
Standard InChI | InChI=1S/C29H24BrN3O4/c1-17-7-12-22-21(15-17)27(19-5-3-2-4-6-19)28(29(37)31-22)23-16-24(18-8-10-20(30)11-9-18)33(32-23)25(34)13-14-26(35)36/h2-12,15,24,32H,13-14,16H2,1H3,(H,35,36)/b28-23- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Noncompetitive NMDA receptor antagonist; displays over 50-fold selectivity for GluN2D- and GluN2C-containing receptors over GluN2B-, GluK2-, GluA1- and GluN2A-containing receptors (IC50 values are 2.7, 8.5, 121, 153, 198 and 206 μM, respectively). Reduces frequency of channel opening. |
DQP 1105 Dilution Calculator
DQP 1105 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7908 mL | 8.9538 mL | 17.9077 mL | 35.8153 mL | 44.7692 mL |
5 mM | 0.3582 mL | 1.7908 mL | 3.5815 mL | 7.1631 mL | 8.9538 mL |
10 mM | 0.1791 mL | 0.8954 mL | 1.7908 mL | 3.5815 mL | 4.4769 mL |
50 mM | 0.0358 mL | 0.1791 mL | 0.3582 mL | 0.7163 mL | 0.8954 mL |
100 mM | 0.0179 mL | 0.0895 mL | 0.1791 mL | 0.3582 mL | 0.4477 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 187-1, N-WASP inhibitor
Catalog No.:BCC5866
CAS No.:380488-27-7
- alpha-Epoxydihydroartemisinic acid
Catalog No.:BCN5434
CAS No.:380487-65-0
- NBMPR
Catalog No.:BCC7516
CAS No.:38048-32-7
- (+)-columbianetin
Catalog No.:BCN2331
CAS No.:3804-70-4
- Tenovin-1
Catalog No.:BCC2239
CAS No.:380315-80-0
- Sulfamonomethoxine sodium
Catalog No.:BCC9157
CAS No.:38006-08-5
- 2-Amino-4'-fluorobenzophenone
Catalog No.:BCC8530
CAS No.:3800-06-4
- LM 22A4
Catalog No.:BCC6239
CAS No.:37988-18-4
- Geranylacetone
Catalog No.:BCN7567
CAS No.:3796-70-1
- tenofovir diphosphate
Catalog No.:BCC6447
CAS No.:166403-66-3
- Tenofovir Alafenamide Fumarate
Catalog No.:BCC8067
CAS No.:379270-38-9
- Tenofovir alafenamide
Catalog No.:BCC8066
CAS No.:379270-37-8
- CMPDA
Catalog No.:BCC6151
CAS No.:380607-77-2
- [(pF)Phe4]Nociceptin(1-13)NH2
Catalog No.:BCC5778
CAS No.:380620-88-2
- Pterolactam
Catalog No.:BCN5435
CAS No.:38072-88-7
- Bosutinib (SKI-606)
Catalog No.:BCC1167
CAS No.:380843-75-4
- TACA
Catalog No.:BCC6564
CAS No.:38090-53-8
- Perampanel
Catalog No.:BCC1847
CAS No.:380917-97-5
- Streptomycin sulfate
Catalog No.:BCC4851
CAS No.:3810-74-0
- Brevianamide F
Catalog No.:BCN6452
CAS No.:38136-70-8
- 28-Hydroxy-3-oxoolean-12-en-29-oic acid
Catalog No.:BCN1449
CAS No.:381691-22-1
- Bephenium Hydroxynaphthoate
Catalog No.:BCC3735
CAS No.:3818-50-6
- 7,8-Dihydroxyflavone
Catalog No.:BCC6072
CAS No.:38183-03-8
- Sulindac
Catalog No.:BCC4861
CAS No.:38194-50-2
Glutamatergic synaptic currents of nigral dopaminergic neurons follow a postnatal developmental sequence.[Pubmed:26074777]
Front Cell Neurosci. 2015 May 29;9:210.
The spontaneous activity pattern of adult dopaminergic (DA) neurons of the substantia nigra pars compacta (SNc) results from interactions between intrinsic membrane conductances and afferent inputs. In adult SNc DA neurons, low-frequency tonic background activity is generated by intrinsic pacemaker mechanisms, whereas burst generation depends on intact synaptic inputs in particular the glutamatergic ones. Tonic DA release in the striatum during pacemaking is required to maintain motor activity, and burst firing evokes phasic DA release, necessary for cue-dependent learning tasks. However, it is still unknown how the firing properties of SNc DA neurons mature during postnatal development before reaching the adult state. We studied the postnatal developmental profile of spontaneous and evoked AMPA and NMDA (N-Methyl-D-aspartic acid) receptor-mediated excitatory postsynaptic currents (EPSCs) in SNc DA neurons in brain slices from immature (postnatal days P4-P10) and young adult (P30-P50) tyrosine hydroxylase (TH)-green fluorescent protein mice. We found that somato-dendritic fields of SNc DA neurons are already mature at P4-P10. In contrast, spontaneous glutamatergic EPSCs show a developmental sequence. Spontaneous NMDA EPSCs in particular are larger and more frequent in immature SNc DA neurons than in young adult ones and have a bursty pattern. They are mediated by GluN2B and GluN2D subunit-containing NMDA receptors. The latter generate long-lasting, DQP 1105-sensitive, spontaneous EPSCs, which are transiently recorded during this early period. Due to high NMDA activity, immature SNc DA neurons generate large and long lasting NMDA receptor-dependent (APV-sensitive) bursts in response to the stimulation of the subthalamic nucleus. We conclude that the transient high NMDA activity allows calcium influx into the dendrites of developing SNc DA neurons.
Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators.[Pubmed:21807990]
Mol Pharmacol. 2011 Nov;80(5):782-95.
The compound 4-(5-(4-bromophenyl)-3-(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dih ydro-1H-pyrazol-1-yl)-4-oxobutanoic acid (DQP-1105) is a representative member of a new class of N-methyl-d-aspartate (NMDA) receptor antagonists. DQP-1105 inhibited GluN2C- and GluN2D-containing receptors with IC(50) values that were at least 50-fold lower than those for recombinant GluN2A-, GluN2B-, GluA1-, or GluK2-containing receptors. Inhibition was voltage-independent and could not be surmounted by increasing concentrations of either coagonist, glutamate or glycine, consistent with a noncompetitive mechanism of action. DQP-1105 inhibited single-channel currents in excised outside-out patches without significantly changing mean open time or single-channel conductance, suggesting that DQP inhibits a pregating step without changing the stability of the open pore conformation and thus channel closing rate. Evaluation of DQP-1105 inhibition of chimeric NMDA receptors identified two key residues in the lower lobe of the GluN2 agonist binding domain that control the selectivity of DQP-1105. These data suggest a mechanism for this new class of inhibitors and demonstrate that ligands can access, in a subunit-selective manner, a new site located in the lower, membrane-proximal portion of the agonist-binding domain.